Skip to main content

Table 1 Peer-reviewed publications describing the use of GEP70/MyPRS® gene expression profiling on patients with multiple myeloma

From: Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use

Date No. patients Patient series Publication
1-Jan-2006 351 Newly diagnosed patients with MM treated with 2 cycles of high-dose melphalan and autologous stem cell transplantation [8]. Shaughnessy JD Jr, Barlogie B. “Using genomics to identify high-risk Myeloma after autologous stem cell transplantation”. Biol Blood Marrow Transplant 2006; 12 (1 Suppl 1):77–80.
25-May-2006 414 Newly diagnosed patients treated with high-dose melphalan-based tandem transplants [9]. Zhan et al. “The molecular classification of multiple myeloma”. Blood 2006; 108(6):2020–2028.
14-Nov-2006 532 Newly diagnosed patients with multiple myeloma (MM) treated on 2 separate protocols [6]. Shaughnessy et al. “A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1”. Blood 2007; 109:2276–84.
9-May-2007 220 Newly diagnosed patients treated with TT2 [10]. Shaughnessy et al. “Testing standard and genetic parameters in 220 patients with multiple Myeloma with complete data sets: superiority of molecular genetics”. Br J Haematol 2007; 137:530–536.
22-Jun-2007 303 Newly diagnosed patients with myeloma treated with Total therapy 3 (incorporating bortezomib into a melphalan-based tandem transplant regimen) [11]. Barlogie et al. “Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3”. Br J Haemotol 2007; 138:176-185
7-Sep-2007 71 Newly diagnosed multiple myeloma patients treated with high-dose melphalan and stem cell transplant [12]. Chng et al. “Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature”. Leukemia 2008; 22:459–61.
1-Dec-2007 326 Newly diagnosed patients with myeloma received a tandem autotransplant regimen [13]. Haessler et al. “Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling”. Clin Cancer Res. 2007; 13(23):7073-7079
15-Jan-2008 156 Relapsed myeloma patients enrolled in the APEX phase 3 clinical trial that compared single-agent bortezomib (B) to high-dose dexamethasone (HD) [14]. Zhan et al. “High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.” Blood 2008; 111(2):968–969.
30-Jun-2008 250 Two hundred fifty patients with myeloma at diagnosis with at least 500,000 available bone marrow CD138+ plasma cells [15]. Decaux etl al. Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome JCO October 10, 2008:4798–4805;
29-Mar-2009 290 Untreated myeloma patients with cytogenetic abnormalities (CA) present in randomly sampled (RS) or focal lesion (FL) bone marrow sites [16]. Zhou et al. “Cytogenetic abnormalities in multiple myeloma: poor prognosis is linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile”. Br J Haematol 2009; 145(5):637-641
25-Jun-2009 120 Myeloma patients previously enrolled in tandem transplantation trial Total Therapy 2 [7]. Nair et al. “Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival”. Blood 2009; 113:6572–5.
14-Mar-2010 258 Newly diagnosed patients with multiple myeloma entered into the MRC Myeloma IX study [17]. Dickens et al. Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome. Clin Cancer Res March 15, 2010 16:1856–1864;
12-Apr-2010 52 Patients newly diagnosed with MM [18]. Zhou et al. “High-risk myeloma is associated with global elevation of MiRNAs and overexpression of EIF2C2/AGO2”. Proc Natl Acad Sci USA 2010; 107(17): 7904-790
30-Sep-2010 757 Previously untreated patients undergoing high-dose chemotherapy [19]. Hose et al. “Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma”. Haematologica 2011; 96(1):87–95.
20-Aug-2010 275 Newly diagnosed patients with symptomatic or progressive myeloma [20]. van Rhee et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010 116:1220–1227;
7-Oct-2010 320 Newly diagnosed patients with MM (Dutch-Belgian Cooperative Trial Group for Hemato-Oncology [21]. Broyl et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010 116:2543–2553;
22-Aug-2011 45 Patients with myeloma receiving initial therapy with lenalidomide and dexamethasone [22]. Kumar et al. “Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone”. Blood 2011; 118(16): 4359–4362.
  1. Publications listed are the first use of GEP70 to stratify patients in the relevant cohort as high or low risk for. Additional publications reanalyzing the same (or subsets of a) patient series are not shown.